Tumour Necrosis Factor Release in Locally Advanced Breast Cancer Patients Receiving Neoadjuvant Docetaxel

NCT01539876 · clinicaltrials.gov ↗
PHASE1
Phase
WITHDRAWN
Status
OTHER
Sponsor class

Stopped Disease Site Team changed research focus unlikely to have sufficient support to complete study

Conditions

Interventions

Sponsor

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's